Tickerover
Healthcare

SYK Stock Analysis

Stryker Corporation · current price $330.67 (+2.66% today)

Solid setup — 3/4 EPS beats. Momentum, fundamentals and macro indicators are aligned.
★★★★
Quality
📊

The six-pillar scorecard

Momentum
50
Drifting higher
price trend
Growth
25
Barely growing
sales & profit growth
Quality
97
High quality
profitability & balance sheet
Valuation
65
Fairly priced
is the price fair?
Sentiment
49
Mixed views
analyst & crowd mood
Risk
76
Low risk
volatility & drawdown

Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.

📉

The picture

What drove the scoreThe seven components contributing most, each read out of 100.
GrowthGrowth: 7070RSI zoneRSI zone: 7070Relative strengthRelative strength: 6565Trend strengthTrend strength: 6565Analyst consensusAnalyst consensus: 7070Near 52w highNear 52w high: 7575FundamentalsFundamentals: 7171
Margin profileWhat survives each step down the income statement.
GrossGross: 65.6%65.6%OperatingOperating: 27.0%27.0%NetNet: 14.4%14.4%Free cash flowFree cash flow: 18.2%18.2%
EPS surpriseReported EPS against estimate, last four quarters.
2026-06: +5.8% vs estimate+6%2026-062026-03: -12.9% vs estimate-13%2026-032025-12: +1.7% vs estimate+2%2025-122025-09: +1.9% vs estimate+2%2025-09
👁

Hype Check

Reading SYK’s price and volume history…

The audit — what has to hold for this thesis

Checking the areas that decide this thesis…

AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.

🛡

Dilution Check

Reading SYK’s filings…

📣

Latest earnings

LAST EARNINGS Stryker Corporation (SYK)

Latest earnings

EPS
$3.19 vs $3.13 est · +1.9% vs estimate BEAT
Revenue
$6.59B · +8.8% YoY
Stock reaction (1M)
-5.0%
Beat streak
3 of last 4 quarters
💰

Valuation

P/E
34.2×
Forward P/E
19.7×
PEG
1.52
Price / Sales
4.9×
Price / Book
5.3×
EV / EBITDA
18.8×
Analyst target
$382.72
Target range
$315.00 – $465.00
Implied upside
+15.7%
🩺

Financial health

Gross margin
65.6%
Operating margin
27.0%
Net margin
14.4%
FCF margin
18.2%
Return on equity
16.5%
Debt / equity
0.64
Revenue growth YoY
+9.4%
EPS growth YoY
+44.1%
📈

Technicals

$281.0052-week range$396.86
RSI (14)
49
50-day MA
$328.66
200-day MA
$339.76
ATR (14)
8.75
Beta
0.77
1-month return
-5.0%
🗓️

Earnings

QuarterEPSEst.SurpriseResult
2025-09-30$3.19$3.13+1.9%Beat
2025-12-31$4.47$4.40+1.7%Beat
2026-03-31$2.60$2.98-12.9%Miss
2026-06-30$3.69$3.49+5.8%Beat
Beat 3 of the last 4 quarters.
🏛️

Ownership & risk

Short % of float
0.02%
Dividend yield
1.09%
Beta
0.77
📰

Latest news on SYK

🔗

Similar stocks in Healthcare

Frequently asked

What is SYK's Quant Score?

Stryker Corporation (SYK) currently has a TickerMover Quant Score of 63/100, rated ★★★★ Quality. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.

Is Stryker Corporation (SYK) a buy?

TickerMover does not give buy or sell recommendations. SYK scores 63/100 (★★★★ Quality) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.

How often is SYK's score updated?

SYK's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.

Get the full live dashboard

Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.

Open the dashboard for SYK →